Some think RNA is undruggable.

We know better.

Medicines that interrupt disease at the source.

Learn more

Enduring Chemistry
makes RNA druggable

Enduring Chemistry forms a permanent covalent bond with a small molecule

The selective chemical scar blocks production of the disease-causing protein

Function requires first binding then bonding, vastly improving selectivity

APPLICATION

Behind each protein is an RNA

We make medicines for diseases that can’t be treated at the protein level

Disordered proteins have no druggable pockets

example

Numerous cancers (STAT3)

Twin proteins can’t be distinguished

example

Lung cancer (SMARCA2/4)

Gene-driven pathologies have no protein to drug

example

Neurodegeneration (Repeat expansions)

Disordered proteins have no druggable pockets

example

Numerous cancers (STAT3)

Twin proteins can’t be distinguished

example

Lung cancer (SMARCA2/4)

Gene-driven pathologies have no protein to drug

example

Neurodegeneration (Repeat expansions)

technology

Pioneering the field of chemo-genomics

Pioneering the field of
chemo-genomics

EXPERIMENT

Each drug is tested simultaneously against numerous RNA targets in the cell

readout

We encode RNA binding events as mutations detectable by next-generation sequencing

data

The result is an interaction map at single-nucleotide resolution across the target-ome

Making chemistry speak the language of genes

The TRANSCEND platform tests drugs against every RNA simultaneously, generating massive interaction datasets powered by the unlimited scalability of NGS

team

Led by experts in RNA, covalent chemistry and AI

Co-founders

Adrian Sanborn, PhD

CEO

Adrian was a founding member of Atomic AI and built the bioscience and drug discovery R&D from inception. His Stanford PhD research in AI & genomics was featured in Time Magazine and The Atlantic.

Jeff Rogers, PhD

CSO

Jeff brings nearly 30 years of expertise in RNA biology, leading RNA-targeting small molecule efforts at Novartis’s RNA Initiative and a Flagship-founded biotech for over a decade.

Ayah Abdeldayem, PhD

Head of Chemistry

Ayah established the covalent chemistry that launched Dunad Therapeutics during her PhD at the University of Toronto, then advanced RNA-targeting drugs as a postdoc with Matt Disney and at Atomic AI.

Scientific advisors

Dan Nomura, PhD

Advisor

Dan pioneered chemoproteomics and induced proximity drug discovery as a Professor at UC Berkeley, co-founding Frontier Medicines and Zenith Therapeutics and advising multiple biotechs and investors.

Patrick Gunning, PhD

Advisor

Pat is a Professor at the University of Glasgow who leads covalent drug discovery. He founded four biotechs including Dunad Therapeutics and Janpix.

Roger Kornberg, PhD

Advisor

Roger is a Professor at Stanford who won the 2006 Nobel Prize in Chemistry for solving the atomic structure of RNA transcription. He has served on numerous boards including PacBio, Teva, and Sangamo.

Supported by the investors that backed Enveda, Basecamp Research, Mammoth, Vir, Octant, and Altos Labs

Scientists on a mission to rewrite what's possible

Get in touch

Some think RNA is undruggable.

We know better.

Behind each protein is an RNA

Endura Therapeutics,The RNA covalency company

Endura Therapeutics,
The RNA covalency company